Improving copper-based treatments for cancer and heart diseases
Official title: Enabling Molecular Approaches for Copper-Based Radiopharmaceuticals
Funded at Brown University · NIH-11021560 · Data updated 2026-11-12
This study is looking at new ways to make copper-based treatments for breast cancer and heart diseases work better and safer, so patients can get more accurate imaging and targeted therapies with fewer side effects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brown University NIH-funded |
| Lab location | 1 site (Providence, United States) |
| Project start | February 1, 2025 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $398,750 |
| NIH project number | 1R35GM157209-01 |
| Project ID | NIH-11021560 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients diagnosed with breast cancer or cardiac disorders who may benefit from advanced imaging techniques or targeted therapies.
✕Less likely to help
Patients with conditions unrelated to cancer or heart diseases may not receive any benefit from this research.
What this research studies
This research focuses on enhancing the effectiveness of copper-based radiopharmaceuticals used for imaging and treating conditions like breast cancer and cardiac diseases. By developing new chelators that stabilize copper isotopes in the body, the study aims to improve the accuracy and safety of these treatments. The approach combines advanced design techniques with laboratory and clinical testing to ensure that the new compounds are both effective and safe for patients. Patients may benefit from more precise imaging and targeted therapies that minimize side effects.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer imaging and treatment options for patients with cancer and heart diseases.
How similar studies have gone: Previous research has shown promising results with copper-based radiopharmaceuticals, indicating potential for success in this novel approach.
Where this research is happening
-
Brown University
Providence, United States Active
Researchers
- Principal investigator: Robinson, Jerome Ronald — Brown University
- Study coordinator: Robinson, Jerome Ronald
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.